Graefes Arch Clin Exp Ophthalmol (2017) 255:1565–1571 DOI 10.1007/s00417-017-3700-3 RETINAL DISORDERS Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy 1,2 1 1 1 Tsutomu Sakai & Noriko Kato & Masaomi Kubota & Hiroshi Tsuneoka Received: 20 September 2016 /Revised: 14 May 2017 /Accepted: 30 May 2017 /Published online: 11 June 2017 Springer-Verlag Berlin Heidelberg 2017 . . Abstract Keywords Aflibercept Photodynamic therapy Purpose To evaluate the outcome of triple therapy of Triamcinolone acetonide Polypoidal choroidal vasculopathy photodynamic therapy combined with injections of intra- vitreal aflibercept (IVA) and subtenon triamcinolone acetonide for polypoidal choroidal vasculopathy (PCV) Introduction resistant to IVA. Methods A retrospective chart review at a single institu- Polypoidal choroidal vasculopathy (PCV) is a distinct clinical tion was conducted to identify patients with PCV resis- entity that differs from exudative age-related macular degen- tant to treatment with IVA who were switched to treat- eration (AMD) in several ways. PCV is characterized by an ment with triple therapy. In total, 13 eyes from 13 pa- abnormal branching vascular network with polypoidal termi- tients were included in the study. Demographic data, nal bulbs in the inner choroids [1–4]. The pathophysiology of visual acuities,
Graefe's Archive for Clinical and Experimental Ophthalmology – Springer Journals
Published: Jun 11, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera